Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Marit M. van Buuren"'
Autor:
Asaf Poran, Dewi Harjanto, Matthew Malloy, Christina M. Arieta, Daniel A. Rothenberg, Divya Lenkala, Marit M. van Buuren, Terri A. Addona, Michael S. Rooney, Lakshmi Srinivasan, Richard B. Gaynor
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Abstract Background The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.
Externí odkaz:
https://doaj.org/article/9f61d50420b745d5900a6a515483100a
Autor:
Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated
Externí odkaz:
https://doaj.org/article/dcfa2791fafa4572a3dce6276ee8be68
Autor:
Inge Verbrugge, Jannie Borst, Marcel Verheij, Ton N. Schumacher, Marit M. van Buuren, Andriy Volkov, Victoria Iglesias-Guimarais, Elselien Frijlink, Paula Kroon
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined, in a poorly immunogenic mouse breast cancer model, the potential of antibody-based immunomodulation and conventional anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92ea48ddcb7cc40245f8b7be500ac89
https://doi.org/10.1158/2326-6066.c.6550047.v1
https://doi.org/10.1158/2326-6066.c.6550047.v1
Autor:
Inge Verbrugge, Jannie Borst, Marcel Verheij, Ton N. Schumacher, Marit M. van Buuren, Andriy Volkov, Victoria Iglesias-Guimarais, Elselien Frijlink, Paula Kroon
Cisplatin modestly reduces the RIT-induced increase in CD8:CD4 T cell ratio and enhances (R)IT-medated control of non-irradiated tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ea8012371431e65f7b05155e4c4a71a
https://doi.org/10.1158/2326-6066.22542798.v1
https://doi.org/10.1158/2326-6066.22542798.v1
Autor:
Cécile Alanio, Francesco Nicoli, Philippe Sultanik, Tobias Flecken, Brieuc Perot, Darragh Duffy, Elisabetta Bianchi, Annick Lim, Emmanuel Clave, Marit M van Buuren, Aurélie Schnuriger, Kerstin Johnsson, Jeremy Boussier, Antoine Garbarg-Chenon, Laurence Bousquet, Estelle Mottez, Ton N Schumacher, Antoine Toubert, Victor Appay, Farhad Heshmati, Robert Thimme, Stanislas Pol, Vincent Mallet, Matthew L Albert
Publikováno v:
eLife, Vol 4 (2015)
Chronic infection perturbs immune homeostasis. While prior studies have reported dysregulation of effector and memory cells, little is known about the effects on naïve T cell populations. We performed a cross-sectional study of chronic hepatitis C (
Externí odkaz:
https://doaj.org/article/d89d3f83b9d7475b9d4f81ba46b5ec3d
Autor:
Daniel Kallin, Marit M. van Buuren, Jessica Kohler, Jonathan McGee, C.M. Nijenhuis, Joost H. van den Berg, Dewi Harjanto, Paul J. Turcott, Janani Sridar, Divya Lenkala, Brian C. McCarthy, Richard B. Gaynor, Michael D. Nelson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. NEO-STI
Autor:
Zhiqin Huang, Pramod K. Srivastava, Song Liu, Jason A. Greenbaum, Dirk Jäger, Jiaqian Wang, Ognjen Milicevic, Willem-Jan Krebber, Barbara Schrörs, Sean Michael Boyle, Michal Bassani-Sternberg, Ana M. Mijalkovic Lazic, Amit A. Lugade, Kristen K. Dang, Han Si, Alessandro Sette, Jeffrey P. Ward, Irsan Kooi, Michael F. Princiotta, Begonya Comin-Anduix, Thierry Schuepbach, Pia Kvistborg, Julia Kodysh, William Chour, Vladimir B. Kovacevic, Jan H. Kessler, Ariella Sasson, Antoni Ribas, Brian Stevenson, Sriram Sridhar, Prateek Tanden, Robert D. Schreiber, Jason Perera, Kathleen C. F. Sheehan, Hira Rizvi, Sachet A. Shukla, Baikang Pei, Han Chang, Bo Li, Ion I. Mandoiu, Cristina Puig-Saus, Beatriz M. Carreno, Si Qiu, Jennifer M. Shelton, Patrick Jongeneel, Qiang Hu, Taha Merghoub, Matthew D. Hellmann, James P. Conway, Francisco Arcila, Ton N. Schumacher, Mathias Vormehr, Christopher A. Morehouse, Patrice Manning, Jonathon Blake, Pornpimol Charoentong, Angela Frentzen, Christopher A. Miller, Michael A. Kuziora, Bin Song, Lei Wei, Martin Löwer, Gabor Bartha, Justin Guinney, Niels Halama, Rolf Hilker, Yinong Sebastian, Veliborka Josipovic, Jason Harris, Geng Liu, Guilhem Richard, Arjun A. Rao, Nikola M. Skundric, Markus Mueller, Daniel K. Wells, Tatiana Shcheglova, Inka Zörnig, Weixuan Fu, John Sidney, Nadine Defranoux, Gabriela Steiner, Joseph D. Szustakowski, Arbel D. Tadmor, Maxim N. Artyomov, Jianmin Wang, George Coukos, Brandon W. Higgs, Milica R. Kojicic, Siranush Sarkizova, Daphne van Beek, Naibo Yang, Robert Ziman, Mignonette H. Macabali, Thomas Yu, Nicolas Guex, Nina Bhardwaj, Lorenzo F. Fanchi, Bjoern Peters, Christian Iseli, Song Wu, Maren Lang, Juliet Forman, Marit M. van Buuren, David Balli, Steven L. C. Ketelaars, Nir Hacohen, Ekaterina Esaulova, Maarten Slagter, Todd Creasy, Robert A. Petit, Yi-Hsiang Hsu, Ravi Gupta, Katie M. Campbell, Pascal Gellert, David Haussler, Jesse M. Zaretsky, Sofie R. Salama, Vanessa M. Hubbard-Lucey, Joel Greshock, Zeynep Kosaloglu Yalcin, Cornelis J. M. Melief, Priyanka Shah, Ioannis Xenarios, Nevena M. Ilic Raicevic, Andrew Lamb, Suchit Jhunjhunwala, Aly A. Khan, David Gfeller, James R. Heath, Richard Chen, Jia M. Chen, Alphonsus H. C. Ng, Elham Sherafat, Ana Belen Blazquez, Leo J. Lee, Beata Berent-Maoz, Cheryl Selinsky, Jasreet Hundal, Eduardo Cortes, Xengie Doan, Sahar Al Seesi, Adam Kolom, Fred Ramsdell, Nicolas Robine, Andrew J. Rech
Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the param
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b788124c42a6ace5b9cb5efa2f3572c
https://resolver.caltech.edu/CaltechAUTHORS:20201019-121956456
https://resolver.caltech.edu/CaltechAUTHORS:20201019-121956456
Autor:
Christina M. Arieta, Richard B. Gaynor, Marit M. van Buuren, Daniel A. Rothenberg, Dewi Harjanto, Michael S. Rooney, Divya Lenkala, Lakshmi Srinivasan, Asaf Poran, Terri A. Addona, Matthew Malloy
Publikováno v:
Genome Medicine, Vol 12, Iss 1, Pp 1-15 (2020)
Genome Medicine
Genome Medicine
BackgroundThe ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity for SARS-CoV-2.MethodsWe
Autor:
Jonathan McGee, Divya Lenkala, Prerna Suri, Gabe S. Sonke, John B. A. G. Haanen, Marit M. van Buuren, Jessica Kohler, Christina M. Arieta, Richard B. Gaynor, C.M. Nijenhuis, Mark DeMario, Brian C. McCarthy, Maarje Rohaan, Susan Hannes, Dewi Harjanto, Daniel Kallin, Paul J. Turcott, Diana Velez, Shirisha Meda
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A212-A212
BackgroundNeoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. Here, we
Autor:
Jared L. Dietze, Daniel A. Rothenberg, Terri A. Addona, Antoine Boudot, Jessica Kohler, Jennifer G. Abelin, Vikram R. Juneja, Paul J. Turcott, Brandon P. Conn, Marit M. van Buuren, Scott P. Goulding, Christopher D. McGann, Richard B. Gaynor, John R. Srouji, Kendra C. Foley, Jae Won Choi, Michael S. Rooney, Divya Lenkala
Publikováno v:
Cell Reports Methods. 1:100084
Summary Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell res